Stock comparison
Arrowhead Pharmaceuticals
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ARWR
Arrowhead Pharmaceuticals
Market cap
$10.56B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ARWR | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 34F | 70B | HAE |
| Benjamin Graham | 70D | 85A | HAE |
| Philip Fisher | 53C | 60C | HAE |
| Peter Lynch | 66C | 54C | ARWR |
| Joel Greenblatt | 42D | 31F | ARWR |
| Charlie Munger | 41D | 54D | HAE |
| Terry Smith | 39D | 55D | HAE |
Side-by-side metrics
| Metric | ARWR | HAE |
|---|---|---|
| Market cap | $10.56B | $2.98B |
| P/E (TTM) | - | 24.8x |
| EV/EBIT | 118.4x | 14.1x |
| ROIC (TTM) | -10.98% | 8.37% |
| Gross margin | 98.98% | 55.74% |
| Net margin | -48.38% | 7.29% |
| Revenue CAGR 5y | 56.5% | 7.65% |
| EPS CAGR 5y | - | 24.62% |
| Debt / Equity | 2.2x | 1.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ARWR leads on
- P/E (TTM)-vs 24.8x+171%
- Revenue CAGR 5y56.5%vs 7.65%+86%
- Market cap$10.56Bvs $2.98B+72%
- Gross margin98.98%vs 55.74%+44%
HAE leads on
- ROIC (TTM)8.37%vs -10.98%+176%
- Net margin7.29%vs -48.38%+115%
- EV/EBIT14.1xvs 118.4x+88%
- Debt / Equity1.5xvs 2.2x+31%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.